Fennec Pharmaceuticals reported total net revenues of $9.7 million for the second quarter of 2025, with double-digit new accounts, including growth in large community practices and academic centers. Initial uptake of PEDMARQSI in the UK and Germany was successful, with more EU launches planned. Japan clinical trial results are expected in the second half of 2025.

Revenue for the second quarter of 2025 was $9.7 million, a 33% increase from the same period in 2024. Selling and marketing expenses were $4.4 million, and general and administrative expenses were $7.0 million. Cash and cash equivalents were $18.7 million as of June 30, 2025. A conference call will be held at 8:30 a.m. ET today.

PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients. Studies show up to 90% of patients treated with cisplatin may develop hearing loss. Fennec Pharmaceuticals is focused on sparing cancer patients further hardship by protecting their ears against cisplatin-induced hearing loss.

Fennec Pharmaceuticals is committed to commercializing PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients. The company has exclusive licensing agreements with Norgine Pharmaceuticals for commercialization in Europe, the UK, Australia, and New Zealand. PEDMARK has received Orphan Drug Exclusivity in the US and Pediatric Use Marketing Authorization in Europe.

Important safety information for PEDMARK includes hypersensitivity reactions, sodium sulfite content, and risks of hypernatremia and hypokalemia. Adverse reactions may include vomiting, nausea, decreased hemoglobin, and hypernatremia. For more detailed prescribing information and safety precautions, visit the PEDMARK website.

For further information, investors can contact Robert Andrade, CFO of Fennec Pharmaceuticals at +1 919-246-5299. For corporate and media inquiries, contact Lindsay Rocco of Elixir Health Public Relations at +1 862-596-1304 or [email protected]. Fennec Pharmaceuticals is dedicated to protecting cancer patients from cisplatin-induced hearing loss and improving their quality of life.

Read more at GlobeNewswire: Fennec Pharmaceuticals Reports Second Quarter 2025